Covalent Development United States

Covalent Development facilite le développement de votre portefeuille clients et de votre chiffre d'affaires en Amérique du Nord. Nous sommes spécialisés dans la vente de services complexes et innovants à l'Industrie Pharmaceutique et Cosmétique.

Based in Central New Jersey, Covalent Development offers to develop US business activities of Biotech companies.  
The state of New Jersey is home to more than 300 biotechnology companies and 20 pharmaceutical and medical technology firms (17 out of the world’s top 20 have major facilities in the state). This incredible concentration offers extraordinary opportunities to develop your business.  
New York, Boston, Washington DC, North Carolina and Philadelphia are close and there is only 3 hours of time difference with West Coast. It makes things easier to reach your prospects and clients!


Basée dans le centre du New Jersey, Covalent Development propose de développer vos activités aux Etats-Unis. 
L'état du New Jersey héberge plus de 300 entreprises de biotechnologie ainsi que 20 sociétés pharmaceutiques et médicales (17 du top 20 sont implantées dans l'état). C'est une localisation idéale pour développer votre business. 
New York, Boston, Washington DC, la Caroline du Nord et Philadelphia sont proches et il n'y a que 3 heures de décalage horaire avec la côte ouest. De quoi faciliter les échanges avec vos prospects et clients ! 

Ms Delphine Davan-Gatti
Ms Delphine Davan-Gatti
Owner, Founder 
Mr Anselmo Rivera
Head of Business Development 

CUNY United States

CUNY is home to more than 100 research centers, institutes and consortia, which provide research opportunities for faculty and students, employment, internships, and special events. These centers focus their efforts on a wide range of areas, including aging, applied sciences, corporate integrity, transportation systems, ethnic studies, performing arts, sustainable energy and urban studies, to name a few.

Many institutions reflect CUNY’s support of state-of-the-art education and research, such as the Institute for Ultrafast Spectroscopy and Lasers. Others exemplify the University’s commitment to service and historic preservation, including the Institute for Criminal Justice Ethics at John Jay College and the Gotham Center for New York City History, founded by Pulitzer Prize-winning historian Mike Wallace.


CUNY United States

Ms Neeti Mitra
University Research Commercialization Manager 

CUNY Institute CoSSMO United States

Our mission is to identify potential projects and participants across CUNY and in the community at large, to help members identify sources of funding and to prepare grant applications, to facilitate the execution of the projects, providing advice, space, and computer facilities, to create research programs by aggregating multiple projects with common defining factors (such programs will promote interactions and networking that will increase the value of the research activities with respect to the contribution of individual projects), to manage program projects with core competencies, and to establish collaborations outside CUNY (national and international)

Professor Felisa Vazquez-Abad
Professor and Executive Director 

CUNY-CITY COLLEGE | the Advanced Vein Visualization, AVV-1 United States

IUSL /Physics Dept. Outcome in Biophotonics Developed at the City University of New York and Lawrence Livermore National Laboratory, the Advanced Vein Visualization, AVV-1 provides a superior illumination and visualization of a patient's veins in both the arm and hand.  The AVV-1 has been designed to help a medical practitioner or nurse to accomplish the task of inserting a needle for an IV or blood draw in a more efficient, timely and safe manner. This will help minimize patient and practitioner stress, treatment delays, and infections from failed attempts. Vein illumination is particularly important when the patient is obese, very young, aged and/or has dark skin. Hopefully, the AVV-1 will soon be on the market at blood test centers and hospitals.

The Advanced Vein Visualization instrument is based on basic research conducted and patented by Robert Alfano and Stavros Demos at the Institute for Ultrafast Spectroscopy and Lasers (IUSL) of The City College of New York (CCNY). Their research was assisted by Michele Alfano-Berwanger

Cushman & Wakefield United States

Cushman & Wakefield is a global leader in commercial real estate services, helping clients transform the way people work, shop, and live. The firm’s 43,000 employees in more than 60 countries provides deep local and global insights that create significant value for occupiers and investors around the world.


agency leasing, global occupier services, asset services, investment management (branded DTZ Investors), capital markets, project & development services, facility services (branded C&W Services), tenant representation and valuation & advisory

Mr Bill Hartman
Executive Vice President 

Cydan: Orphan Drug Accelerator United States

Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.


Orphan Drugs, Rare Diseases, Genetic Disorders

Ms Vered Bisker-Leib
Chief Business Officer 

d3 Medicine United States

We work with like-minded highly innovative people to develop meaningful medicines and create impactful health care solutions.

We are:

Strategic partners in global drug development
  • - Provide comprehensive scientific, strategic, and regulatory support to plan, manage, and execute full development programs  
  • - Formulate early development, clinical pharmacology and translational medicine strategies to fast-track preclinical development to POC
  • - Improve decision making with an emphasis on quantitative analytics and use of modeling and simulation
  • - Provide a fully capable and experienced drug development team, or individual components based on client needs
Advisors in technical due diligence and business development strategy
Mr Patrick Smith, PharmD
Executive Director  

Darmiyan LLC United States

Darmiyan will offer a series of diagnostic tools aimed at early detection of complex brain diseases including neurodegenerative disorders. Darmiyan will get brain MRI data from human patients to elucidate the current condition, and which disease state the brain is progressing toward. The significance of Darmiyan’s innovation is invaluable potential to diagnose disease potential before severe symptoms develop. This novel insight originates with our technology to extract information not from the brain cells/ neurons, which exhibit abnormality only after extensive damage and cell death occurs, but from the immediate environment around them, which is called extracellular space (ECS). The ECS is often thought of as just intercellular “space,” but in reality it is the electrical and chemical pathway between all brain cells that plays an essential role in brain function and drug delivery.

Dr Padideh Kamali-Zare

DBCapital United States

Mr David Bildner
Managing Partner